Christopher Bunka

CIK: 0001103780

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LEXX

Lexaria Bioscience Corp.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

LEXX
Lexaria Bioscience Corp.
Mar 17, 2026
Gift(G)
Direct
100K shares-
LEXX
Lexaria Bioscience Corp.
Jul 30, 2025
Purchase(P)
Indirect
11.9K shares at avg. $0.91$11K
LEXX
Lexaria Bioscience Corp.
Jul 29, 2025
Purchase(P)
Indirect
15.6K shares at avg. $0.92$14K
LEXX
Lexaria Bioscience Corp.
May 15, 2025
Award(A)
Stock Options
Direct
11K shares-
LEXX
Lexaria Bioscience Corp.
Jan 7, 2025
Award(A)
Direct
100K shares-

		Type	Shares	Price		Ownership
Mar 17, 2026	LEXX Lexaria Bioscience Corp.	Gift(G)	100,000	-	$0	Direct
Jul 30, 2025	LEXX Lexaria Bioscience Corp.	Purchase(P)	11,900	$0.91	$10,866	Indirect
Jul 29, 2025	LEXX Lexaria Bioscience Corp.	Purchase(P)	15,600	$0.92	$14,375	Indirect
May 15, 2025	LEXX Lexaria Bioscience Corp.	Award(A) Stock Options	11,000	-	-	Direct
Jan 7, 2025	LEXX Lexaria Bioscience Corp.	Award(A)	100,000	-	$0	Direct

1-5 of 5 transactions

About BUNKA CHRISTOPHER

BUNKA CHRISTOPHER (SEC CIK 0001103780) files insider reports with the SEC as Director of Lexaria Bioscience Corp. (LEXX).

Signal8 holds 4 ownership filings by BUNKA CHRISTOPHER, all Form 4s, filed between Jan 10, 2025 and Mar 18, 2026. Those filings report 5 transactions, from Jan 7, 2025 to Mar 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BUNKA CHRISTOPHER's filings is in KELOWNA.

Recent filings by BUNKA CHRISTOPHER

Mar 17, 2026: Gift of LEXX shares (Form 4, code G).
Jul 30, 2025: Open-market purchase of LEXX shares (Form 4, code P).
Jul 29, 2025: Open-market purchase of LEXX shares (Form 4, code P).
May 15, 2025: Grant or award of LEXX derivative securities (Form 4, code A).
Jan 7, 2025: Grant or award of LEXX shares (Form 4, code A).

Other insiders filing for Lexaria Bioscience Corp. (LEXX)

DOCHERTY JOHN MARTIN, President
Carle Vanessa, Secretary
CHRISTOPHER RICHARD, Chief Executive Officer
Shankman Michael Elliot, Chief Financial Officer
Bhullar Baljinder, Director
Baxter Nicholas W, Director

How to read Form 4 transaction codes